SYN-010 42 mg

DRUG2 trials

Sponsors

Theriva Biologics, Inc., Cedars-Sinai Medical Center

Conditions

Irritable Bowel Syndrome With ConstipationIrritable Bowel Syndrome With Constipation (IBS-C)

Phase 2

A Study of the Effect of SYN-010 on Subjects With IBS-C

CompletedNCT02495623

Theriva Biologics, Inc.Irritable Bowel Syndrome With Constipation (IBS-C)

Start: 2015-06-30End: 2015-11-30Updated: 2018-11-27

Efficacy and Safety of SYN-010 in IBS-C

TerminatedNCT03763175

Cedars-Sinai Medical CenterIrritable Bowel Syndrome With Constipation

Start: 2018-12-24End: 2020-10-09Updated: 2022-07-13

Related Papers

Methanogens and Hydrogen Sulfide Producing Bacteria Guide Distinct Gut Microbe Profiles and Irritable Bowel Syndrome Subtypes

The American Journal of Gastroenterology2022-09-06142 citations

S499 Elevations in Breath Methane Are Associated With Lower Heart Rate: Post-Hoc Analysis of a Double Blind Randomized Control Trial

The American Journal of Gastroenterology2021-10-01

SYN-010 Modified-Release Lovastatin Does Not Significantly Alter Lipid Parameters at Doses that Reduce Methane and Alleviate Symptoms in Patients Suffering Irritable Bowel Syndrome with Constipation (IBS-C)

The American Journal of Gastroenterology2016-10-011 citations

Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway.

2016-04-0818 citations

Referee report. For: Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway [version 1; referees: 1 approved with reservations]

Faculty of 1000 Research Ltd2016-01-01

Referee report. For: Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway [version 3; referees: 2 approved, 1 approved with reservations]

Faculty of 1000 Research Ltd2016-01-01

Referee report. For: Lovastatin lactone may improve irritable bowel syndrome with constipation (IBS-C) by inhibiting enzymes in the archaeal methanogenesis pathway [version 2; referees: 2 approved with reservations]

Faculty of 1000 Research Ltd2016-01-01